Caris Life Sciences Inc.
CAI | NASDAQ
$32.12
-$2.21 (-6.44%)
Nov 2, 2026, 3:57 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|
PE Ratio | -14.13 | -10.37 | -15.38 | -17.83 | 18.06 |
PEG Ratio | 0.48 | -0.21 | -0.97 | n/a | -1.83 |
PS Ratio | 9.38 | 17.30 | 23.29 | 27.60 | 1.71 |
PB Ratio | 13.19 | -2.85 | -3.32 | -4.19 | 0.72 |
P/FCF Ratio | 113.87 | -28.11 | -23.89 | -21.75 | 8.73 |
P/OCF Ratio | 91.60 | -29.08 | -25.83 | -24.97 | 1.81 |
OCF/S Ratio | 10.24 | -59.48 | -90.19 | -110.53 | 94.22 |
Debt / Equity Ratio | 0.66 | -0.17 | -0.10 | -0.16 | 2.49 |
Quick Ratio | 7.85 | 1.06 | 2.04 | 3.43 | 0.67 |
Current Ratio | 7.85 | 1.30 | 2.55 | 3.77 | 0.67 |
Asset Turnover | 0.72 | 1.20 | 0.74 | 0.36 | 0.11 |
Interest Coverage | 0.79 | -5.14 | -10.11 | -11.83 | 2.26 |
Return on Equity | -93.18% | 11.28% | 15.92% | 18.85% | 3.95% |
Return on Assets | -47.79% | -82.01% | -82.69% | -44.72% | 1.06% |
Return on Invested Capital | 4.52% | -105.17% | -98.47% | -49.52% | 5.28% |
Dividend Yield | n/a | n/a | n/a | n/a | 3.52% |
Payout Ratio | n/a | n/a | n/a | n/a | 63.84% |
FCF Payout Ratio | n/a | n/a | n/a | n/a | 31.74% |
Gross Profit Margin | 66.40% | 43.37% | 29.17% | 30.96% | 62.64% |
Net Profit Margin | -66.25% | -68.38% | -111.53% | -124.12% | 9.43% |
Pretax Profit Margin | -8.38% | -68.38% | -111.53% | -124.12% | 10.04% |
Operating Profit Margin | 5.56% | -62.37% | -104.38% | -122.16% | 47.31% |
FCF Margin | 8.24% | -61.52% | -97.48% | -126.88% | 19.58% |
EBITDA Margin | 1.40% | -44.38% | -85.19% | -95.13% | 86.55% |
Add to Watchlist
Select watchlists to add or remove CAI